drugset / Trial / NCT01396187
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple ascending doses of PF-05231023.
Timeline
- Start
- 2011-07
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-05231023 | Protein / enzyme biologic | 5 mg | Intravenous |
| Subject | PF-05231023 | Protein / enzyme biologic | 25 mg | Intravenous |
| Subject | PF-05231023 | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | PF-05231023 | Protein / enzyme biologic | 200 mg | Intravenous |